Compare Nvidia Corp (NVDA) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nvidia Corp vs Revvity Inc — how do they compare? Nvidia Corp trades at $233.74 (market cap $5.57T), while Revvity Inc trades at $152.05 (market cap $16.98B). The key difference: Nvidia Corp is far larger — about 328× Revvity Inc's market cap, and Nvidia Corp pays the higher dividend (0.43%). Which is the better fit depends on your goals — on Pluang, investors hold Nvidia Corp for 115 Days and Revvity Inc for 12 Days on average.
| NVDA | RVTY | |
|---|---|---|
Market Cap | $5.57T | $16.98B |
Volume | 117,720,595 | 1,456,900 |
Sector | Technology | Health |
52-Week High | $239.27 | $157.36 |
52-Week Low | $165.17 | $82.26 |
Typical Hold Time | 115 Days | 12 Days |
Enterprise Value | $5.54T | $19.30B |
Dividend Yield | 0.43% | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVIDIA (NVDA) trades at $237.36, down 0.8% on the day, amid a broader tech sector rotation. The stock exhibits a bullish technical trend, supported by strong fundamentals including a 55.84% net income margin and consistent earnings beats. Revenue growth accelerated to $130.50 billion in 2025, with analyst consensus remaining overwhelmingly positive.
The outlook for NVDA is favorable, driven by sustained AI chip demand and a $339.17 average price target implying significant upside. Key risks include heightened competition, market volatility from geopolitical tensions, and the stock's premium valuation. Long-term growth prospects remain robust, though near-term volatility may persist.
RVTY trades at $153.60, up 0.2% today and near its 52-week high of $158.28 (Defense World, 2026-10-01). The stock shows a bullish technical trend with strong moving average signals and has beaten earnings estimates for three consecutive quarters. Recent developments include the launch of a CE-IVDR-certified T1D screening kit in Europe (Business Wire, 2026-09-24) and the acquisition of Human Cell Design to expand metabolic disease research tools (Business Wire, 2026-09-09).
The outlook is positive, supported by earnings momentum, strategic acquisitions, and analyst optimism. However, the stock trades at a premium valuation with a P/E of 73.15, and near-term risks include margin pressures in China and rich valuation limiting upside beyond consensus targets. Revenue stability but slight profit margin compression in 2026 warrants monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
